Primary:
To compare the efficacy of Rasburicase versus allopurinol in controlling tumor lysis-related
hyperuricemia in Chinese patients with leukemia or lymphoma.
Secondary:
To compare the efficacy and safety of Rasburicase versus allopurinol in Chinese patients
stratified according to disease (leukemia or lymphoma ).